Building on post #5 rather than restating it.
2.5 mg starting dose is well covered in the tag pages, and the older discussions are better than the recent ones because they were argued out properly. Worth twenty minutes before adding to this one.
Topic summary
The 2.5 mg starting dose is not a therapeutic dose — why that matters
This is a generated summary. It shows the 9 most-liked posts from a topic of 137, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
Everything in post #17 holds. The case it does not cover is the one I have.
Research-use-only tirzepatide is not approved for human use and is not made to pharmaceutical standards. Anyone discussing it here is describing what they did, not recommending it.
On reflection I would soften that slightly.
30 likes 5mo
Worth separating two things that post #21 runs together.
Titration schedules for tirzepatide have more dose steps than semaglutide partly because the compound is more potent and partly because the clinical programme used a finer gradation. That does not mean you cannot escalate on a coarser schedule if that suits you — the published schedule is not a lower bound.
30 likes 5mo
ma.balogun, post #30: Picking up post #29: that is the part I would want checked first. 2.5 mg starting dose is a question about a distribution, not about a value, and treating it as a value is what produces the confident wrong answers. Go to post
That matches what I have seen, for whatever a single anecdote is worth.
I had written a reply contradicting post #56 and deleted it. Here is what survived.
Research-use-only tirzepatide is not approved for human use and is not made to pharmaceutical standards. Anyone discussing it here is describing what they did, not recommending it.
I would treat the number as indicative rather than as a measurement.
29 likes 4mo
Narrowing post #87, because the general version has more than one answer.
Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are more persuasive and less informative than the mean. They depend entirely on where the threshold was drawn.
On balance I think that is right, and I would not bet much on it.
29 likes 3mo
v.salgado, post #76: Coming back to post #75, because the follow-up matters more than the original answer. Since 2.5 mg starting dose keeps coming up, it should probably be a maintained page rather than a recurring thread. I am happy to draft it if someone with more direct experience will review it. Go to post
Small methodological point on 2.5 mg starting dose: repeating a measurement is cheap and resolves most of what is being argued about here at no cost to anyone.
ra.mensa, post #2: On 2.5 mg starting dose: the maintained page in the documentation commons covers the general case with citations and a review date, which is more reliable than any reply here including this one. Go to post
On 2.5 mg starting dose, the part that usually goes wrong is that the question is asked as though it has one answer. It has a range, and the width of the range is the interesting bit.
If you can post the two or three numbers you are working from, several people here will check the arithmetic rather than argue about the conclusion.
k.salinas, post #9: Worth separating two things that post #5 runs together. Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are more persuasive and less informative than the mean. They depend entirely on where the threshold was drawn. Someone should write this up properly, and it should probably not be… Go to post
SURMOUNT-4's randomised withdrawal design is the strongest available evidence about what happens on stopping. It says nothing about a lower maintenance dose, because the comparison was continue versus placebo rather than continue versus less.
Read the full topic (137 posts)
This topic was referenced in
- Revisiting: Why tirzepatide titration schedules have more steps than semaglutide'sCompounds › Tirzepatide · 101 replies
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — setting out what I have, and where I think it stops being reliable. I have spent a fortnight trying to pin tirzepatide in type 2…
|
+150 | 163 | 22k | 11mo |
|
[2026 update] Comparing tirzepatide and semaglutide is harder than the tables suggest
Comparing tirzepatide and semaglutide is harder than the tables suggest Writing it up because I had to work it out twice and would rather nobody else did. Putting the numbers in the first post, because a…
|
2 | 23k | 21mo | |
|
SURPASS-2 and the comparator dose question that will not go away — what changed since
Posting this under the heading it deserves: SURPASS-2 and the comparator dose question that will not go away — what changed since Everything below is what sits behind that. What changes if the standard…
|
+2 | 6 | 5.5k | 7h |
|
Tirzepatide molecular mass and the charge states you would expect on ESI
Tirzepatide molecular mass and the charge states you would expect on ESI Writing it up because I had to work it out twice and would rather nobody else did. Tirzepatide molecular mass keeps being re-asked here…
|
+36 | 40 | 44k | 11mo |
|
Tirzepatide storage and stability: what is published versus what is assumed — does this still hold?
The question in the title: Tirzepatide storage and stability: what is published versus what is assumed — does this still hold? I will give what I have already checked below so nobody repeats it. Asking about…
|
+15 | 19 | 930 | 18mo |
Related topics — sharing the tags SURPASS programme, SURMOUNT programme, effect size
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Semaglutide in people without diabetes: what the evidence base looks like
Semaglutide in people without diabetes: what the evidence base looks like Writing it up because I had to work it out twice and would rather nobody else did. What changes if the standard account of semaglutide…
|
+2 | 6 | 18k | 17mo |
|
Why a preprint's supplementary material is often the best part
Why a preprint's supplementary material is often the best part I have a specific reason for asking rather than idle curiosity, and the context is below. A question about how this site should cite something…
|
+38 | 42 | 863 | 22mo |
|
Why semaglutide's albumin binding is the whole reason weekly dosing works
Asking directly, because I could not find a straight answer: Why semaglutide's albumin binding is the whole reason weekly dosing works Putting the numbers in the first post, because a question about a…
|
2 | 63k | 5mo | |
|
Reading a combination trial: attributing effect to components
On the subject in the title: Reading a combination trial: attributing effect to components Working notes rather than a conclusion. Collecting what is known about reading a combination trial in one place,…
|
4 | 19k | 11mo | |
|
Coming back to: Amylin analogue mechanism: satiety signalling separate from GLP-1
On the subject in the title: Amylin analogue mechanism: satiety signalling separate from GLP-1 Working notes rather than a conclusion. Trying to work out what would count as evidence on Amylin analogue…
|
+27 | 31 | 671 | 12mo |